Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors
WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq:HOWL), an innovative biopharmaceutical company pioneering the development of novel, conditionally activated INDUKINE™ therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the appointment of Michael B. Atkins, M.D., to its Board of Directors.
Related news for (HOWL)
- Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer
- 24/7 Market News Snapshot 08 October, 2025 – Werewolf Therapeutics, Inc. Common Stock (NASDAQ:HOWL)
- Don’t Miss Out: MoBot’s Latest Stock Updates 09/22/25 05:00 PM
- MoBot alert highlights: NASDAQ: LIMN, NASDAQ: SLE, NYSE: BFLY, NASDAQ: SLNH, NASDAQ: HOWL (09/22/25 04:00 PM)
- MoBot alert highlights: NASDAQ: KITT, NASDAQ: VUZI, NASDAQ: HOWL, NASDAQ: BETRW, NASDAQ: KOD (09/22/25 01:00 PM)
